Globe iconBenelux site

ATNAHS added Bonviva (ibandronic acid) to their portfolio of heritage brands in 2017

In 2017, ATNAHS acquired the worldwide marketing and distribution rights to Bonviva (excluding Japan and the US) from Roche.

Bonviva is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.1

History and development of Bonviva

Ibandronic acid was originally patented by Boehringer Mannheim in 1986 and licensed for the treatment of tumour-induced hypercalcaemia in 1996.2

Bonviva (ibandronic acid) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used to treat osteoporosis and were introduced into clinical practice over 40 years ago.3

The oral version of Bonviva (ibandronic acid), now marketed across the world by ATNAHS (not in the US and Japan), was, in 2005, the last oral bisphosphonate licensed for the treatment and prevention of osteoporosis in postmenopausal women.4

When it received its licence as a once-monthly oral tablet in March 2005,5 it made Bonviva the first once-monthly tablet for postmenopausal osteoporosis.5

Network of lights over the globe

A global brand beating all
expectations Bonviva market valued at nearly $1.2 billion in the year 20096

By 2009 Bonviva was in the top 100 globally best-selling pharmaceutical brands with annual sales estimated at $1,161 million.6

A therapeutic solution that is becoming increasingly more important

Osteoporosis is a bone reabsorption disease whose incidence is growing as the population ages.7. It is estimated that currently over 200 million women globally are affected by this insidious disease which shows no clinical manifestations until there is a fracture.7

Based on the statistics of the International Osteoporosis Foundation, it is predicted that worldwide 1 in 3 women and 1 in 5 men over 50 years will experience osteoporotic fractures in their lifetime.7

Disclaimer

All of the information presented above is factual historical information that is available in the public domain and is included in good faith. It is not the intention to make any new or fresh claims nor to be promotional for the product in question.

References

  1. Bonviva 150 mg film-coated tablets, Summary of Product Characteristics.
  2. Boehringer Mannheim GmbH DE3623397. Available from: https://patents.google.com/patent/DE60317061D1/en#patentCitations [Last accessed January 2021].
  3. Kuźnik A, et al. Bisphosphonates—much more than only drugs for bone diseases. Eur J Pharmacol. 2020 Jan 5;866:172773. Available from: https://www.sciencedirect.com/science/article/pii/S0014299919307253#bib117 [Last accessed January 2021].
  4. The pharmaletter. Available from: https://www.thepharmaletter.com/article/roche-gsk-launches-bonviva [Last accessed January 2021].
  5. Roche Data on File. Sept 2005. Available from: https://www.sec.gov/Archives/edgar/vprr/0501/05011194.pdf [Last accessed January 2021].
  6. Top Pharmaceutical Products by Worldwide Sales in 2009. Available from: https://njardarson.lab.arizona.edu/sites/njardarson.lab.arizona.edu/files/Top200PharmaceuticalProductsByWorldwideSalesin2009.pdf [Last accessed January 2021].
  7. Sözen T, et al. An overview and management of osteoporosis. Eur J Rheumatol 2017 Mar; 4(1): 46–56. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335887/ [Last accessed January 2021].

For further product information please follow this link to the relevant product page on this site.